Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor…
Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate
Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of two posters at the 19th International Myeloma Society (IMS) Annual Meeting.
Biomea Fusion: Q2 Earnings Insights
Biomea Fusion (NASDAQ:BMEA) reported its Q2 earnings results on Monday, August 1, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Biomea Fusion Q2 EPS $(0.59) Down From $(0.33) YoY
Biomea Fusion (NASDAQ:BMEA) reported quarterly losses of $(0.59) per share. This is a 78.79 percent decrease over losses of $(0.33) per share from the same period last year.
Biomea Fusion Commences Initial-Stage Study For Plasma Cell Cancer Setting
Biomea Fusion (NASDAQ: BMEA) has dosed the the first patient in the multiple myeloma (MM) cohort of the Phase I clinical trial evaluating BMF-219, a covalent menin inhibitor.
Multiple myeloma (MM) is a cancer of plasma cells, which make antibodies (immunoglobulins) and are mainly located in the bone marrow.
69 Biggest Movers From Yesterday
Gainers
Powerbridge Technologies Co., Ltd. (NASDAQ: PBTS) shares climbed 189.9% to close at $1.12 on Thursday.
79 Biggest Movers From Yesterday
Gainers
AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it as a class II medical device.
HC Wainwright & Co. Assumes Biomea Fusion at Buy, Announces Price Target of $16
HC Wainwright & Co. analyst Joseph Pantginis assumes Biomea Fusion (NASDAQ:BMEA) with a Buy rating and announces Price Target of $16.